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1521-690X/© 2016 Elsevier Ltd. All rights reservedNon-alcoholic fatty liver disease (NAFLD) covers a spectrum of liver
disease from simple steatosis to non-alcoholic steatohepatitis
(NASH) and cirrhosis. NAFLD is commonly associated with features
of the metabolic/insulin resistance syndrome (‘Metabolic/Obese
NAFLD’) and may therefore predict type 2 diabetes (T2DM). For
this review, we searched for prospective studies examining
whether NAFLD predicts T2DM, and if so, whether this occurs
independently of factors such as age and obesity. These studies
included NAFLD diagnosed by ultrasonography (n ¼ 6) or liver
enzymes (n ¼ 14). All ultrasonography studies found NAFLD to
predict the risk of T2DM independently of age, and in 4 out of 6
studies NAFLD was also a predictor independently of BMI. NAFLD
was a predictor of T2DM in all 14 studies where NAFLD was
diagnosed by liver enzymes. In 12 of these studies, ALT or AST or
GGT were significant predictors of T2DM risk, independently of age
and BMI. NAFLD, however, is heterogeneous and may also be
caused by common genetic variants. The I148M variant in PNPLA3
and the E167K variant in TM6SF2 are both associated with
increased liver fat content, but not features of the metabolic/in-
sulin resistance syndrome. These genetic forms of NAFLD predict
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and obesity and support the role of hepatic insulin resistance in
the pathogenesis of this disease.
© 2016 Elsevier Ltd. All rights reserved.Introduction
Non-alcoholic fatty liver disease (NAFLD) is defined as hepatic steatosis not caused by excess use of
alcohol (>20 g/day in women, >30 g/day in men), viruses such as hepatitis B or C, autoimmune hep-
atitis, use of hepatotoxic drugs or other compounds, or rare genetic forms [1]. It covers a range of
conditions from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFLD is
currently the most common liver disorder with an estimated worldwide prevalence of 25% [2].
Depending on the method of diagnosis, 65e87% of patients with type 2 diabetes (T2DM) have NAFLD
[3,4]. NAFLD is the second most common cause of being on awaiting list for a liver transplant in the US
[5] and the most common cause of hepatocellular carcinoma (HCC) in both US [6] and UK [7].
The metabolic/insulin resistance syndrome is a well-established predictor of T2DM, although overt
hyperglycemia only develops in those whose beta-cells fail to sustain hyperinsulinemia in the face of
insulin resistance [8]. The liver is the site of production of glucose and very low-density lipoprotein
(VLDL) -triglycerides. In subjects with ‘metabolic/obese NAFLD’, the liver is insulin resistant leading to
overproduction of both glucose and VLDL [8]. Glucose in turn stimulates insulin secretion thereby
inducing hyperinsulinemia. The increase in VLDL leads to lowering of the concentration of high-density
lipoprotein (HDL) cholesterol. These changes are often observed in obese subjects, but are also
observed independently of obesity [9]. NAFLD is thus closely linked to the pathogenesis of the meta-
bolic syndrome raising the possibility that NAFLD predicts T2DM, even independently of obesity.
In addition to the association of NAFLD with the metabolic/insulin resistance syndrome, two
common genetic variants increase the risk of NAFLD. A variant in the patatin-like phospholipase
domain-containing 3 (PNPLA3) (rs738409[G], encoding I148M) confers to NAFLD susceptibility by
increasing liver fat content, risk of inflammation, and fibrosis (‘PNPLA3 NAFLD’) [10,11]. Genetic
variation in the transmembrane 6 superfamily member 2 (TM6SF2) (rs58542926[T], encoding E167K) is
also associated with liver fat accumulation and increased risk of NASH (‘TM6SF2 NAFLD’) [12,13]. In-
sulin resistance is not a characteristic of these two conditions [14], although genetic and metabolic
causes of NAFLD may both exist in the same person [15].
The ensuing discussion is focused on reviewing studies which have examined whether NAFLD,
diagnosed either by liver enzymes, ultrasonography, other imaging techniques, or by liver biopsy,
predicts T2DM, and if so, whether this is observed independently of obesity and other established
predictors of T2DM. We will also briefly comment on whether and why NAFLD should be screened for
in the diabetes clinic.Methods
Data sources and searches
This systematic reviewwas performed as suggested by the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) group [16]. We searched MEDLINE using the terms “fatty liver”,
“diabetes”, and “ultrasound” for publications with NAFLD diagnosed by ultrasonography, “magnetic
resonance spectroscopy” for those with NAFLD diagnosed by 1H-MRS, and “biopsy” for those with
NAFLD diagnosed by biopsy. In addition, we used the terms “fatty liver”, “steatosis”, “liver enzymes”,
“transaminases”, “alanine aminotransferase” (ALT), “aspartate aminotransferase” (AST), “gamma-glu-
tamyltransferase” (GGT), and “diabetes incidence” while searching for publications in which NAFLD
had been diagnosed by using liver enzymes. All searches were performed by the end of February 2016.
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Inclusion criteria
We included prospective longitudinal cohort studies investigatingwhether baseline NAFLD predicts
the development of T2DM. We included only publications in English.
Exclusion criteria
Since serum or plasma liver enzyme concentrations and liver fat content may increase due to other
reasons than NAFLD [17,18], we excluded studies which did not mention exclusion of subjects with
hepatitis B or C, cirrhosis or malignancy, and those in which alcohol consumption was not assessed or
the analyzes were not adjusted for alcohol consumption.
Results
Study selection
The searches resulted in 1718 potentially relevant citations; NAFLDwas defined using liver enzymes
in 810, ultrasonography in 605, 1H-MRS in 247, and liver biopsy in 56. After screening the titles and
abstracts of these citations, 54, 30, one and four, respectively, remained for further evaluation. Based on
full-text judgment, we excluded i) 30 articles which were not prospective cohort studies, ii) 22 articles
which did not adjust their analyzes for alcohol use or exclude other liver diseases, iii) 15 articles in
which the above listedmethodswere not used to diagnose NAFLD, and iv) two citationswhich only had
an abstract available. Thus, we included a total of 20 publications which are listed in Tables 1 and 2. We
did not identify any longitudinal studies investigating whether 1H-MRS-determined liver fat content or
liver histology predict T2DM.
Study characteristics
Table 1 shows details of the six studies that used ultrasonography to diagnose NAFLD. All except one
small study included subjects of Asian origin (Table 1). The mean age of study subjects ranged from 37
to 49 years and BMI from 23 to 27 kg/m2. Duration of follow-up varied from three to 10 years. In four of
the six studies [19e22], T2DMwas diagnosed based on a fasting plasma or serum glucose7.0 mmol/L,
HbA1c 6.5%, a 2-hour glucose concentration 11.1 mmol/L during a 75 gr oral glucose tolerance test
(OGTT), and/or use of glucose-lowering therapy. Okamoto et al. defined hyperglycemia as a fasting
plasma glucose concentration >6.1 mmol/L or HbA1c >6.4% [23], whilst Zelber-Sagi et al. used cut-offs
of 5.6 mmol/L and 5.7%, respectively [24].
Table 2 shows details of the 14 studies in which used liver enzymes to diagnose NAFLD. The mean
age of study subjects ranged from 44 to 61 years and BMI from 23 to 28 kg/m2. The duration of follow-
up ranged from two to 20 years. Half of the studies included only men. T2DM was defined as a fasting
glucose7.0 mmol/L or use of diabetes medication in nine studies [25e33]. An OGTT was performed in
three studies [29,32,34] and HbA1c measured in one study [33]. Questionnaires or patient records were
used for diagnosis of T2DM in four studies [35e38]. Most of the studies divided the subjects at baseline
by quartiles or quintiles of liver enzymes and compared the risk of diabetes in highest quarter/fifth
with the lowest quarter/fifth. Two studies with slightly different study designs included subjects from
the same cohort [26,27].
Ultrasonography-diagnosed NAFLD and T2DM
Each of the six studies using ultrasonography to diagnose NAFLD showed that NAFLD predicted
T2DM independently of baseline age. NAFLD also remained a significant predictor of T2DM in four out
of the five studies, after adjustment for BMI (Table 1). NAFLD also predicted T2DM independently of
several other factors such as sex, family history of diabetes, HDL-cholesterol, triglycerides, high-
sensitivity C-reactive protein, insulin resistance by Homeostasis Model Assessment for insulin resis-
tance (HOMA-IR), physical activity, and smoking status (Fig. 1).
Table 1
NAFLD as a predictor of type 2 diabetes diagnosed by ultrasonography in prospective studies.
Cohort and
year
N (men, %) Age
(years)











42.7 22.5 10 T2DM
þIFG
No No (age, gender, FPG, HbA1c,












42.5 24.2 3.8 T2DM e Age, WC, TG, HDL, systolic BP,
hsCRP, HOMA, creatinine,
family history T2DM, exercise,
MetS








(52.5) (24.0) 3 T2DM Yes Age, gender, WC, ALT, family






36.8 23.3 5.1 T2DM Yes Age, gender, smoking, alcohol,
exercise, family history of
T2DM, cholesterol, TG, HDL,
HOMA, hsCRP
Low NFS HR 1.81 (1.61e2.04)





48.8 26.6 6.8 T2DM
þIFG
Yes Age, gender, family history of
T2DM, fS-insulin, adiponectin,
fS-glucose, physical activity
Normal US OR 2.95 (1.03e8.44)
HRI OR 7.77 (1.82e33.26)
ALT, alanine transferase; BP, blood pressure; DM, diabetes mellitus, fS, fasting serum; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin A1c, HDL, high-density lipoprotein
cholesterol; HOMA, homeostasis model assessment for insulin resistance; HR, hazard ratio; HRI, hepato-renal ultrasound index; hsCRP, high-sensitivity C-reactive protein; IFG, impaired
fasting glucose; MetS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; NFS, NAFLD fibrosis score; OR, odds ratio; T2DM, type 2 diabetes; TG, triglyceride; US, ultrasonography;
WC, waist circumference.
a Unadjusted estimate.




































Independent of other confounders Effect estimate (95% CI)a
British men
BRHS, UK, 1998 [35]
7458
(100.0%)
40e59 e 12.8 GGT Yes Age, physical activity, alcohol, smoking,
prevalent CHD






25e55 e 4 GGT, ALT Yes Age, smoking, exercise, family history
of T2DM, FPG, alcohol
Highest vs. lowest concentration
group with alcohol <90 g/week





46.5 23.3 7 GGT Yes Age, family history of T2DM, alcohol,
smoking, physical activity, systolic BP,
cholesterol, TG, FPG, white blood count






e e 7 GGT, ALT Yes Age, family history of T2DM, alcohol,
smoking, physical activity, FPG, white
blood count, other liver enzymes
Quintiles Q5 vs. Q1







55.4 26.0 4.9 ALT Yes Age, smoking, systolic BP, cholesterol/
HDL ratio, TG, alcohol, FPG







47.1 28.0 7 AST Yes Age, gender, WC, alcohol, FSI Quartile Q4 vs. Q1e3
OR 1.67 (1.06e2.64)
British men
BRHS, UK, 2005 [36]
3500
(100.0%)
60e79 e 5 GGT, ALT Yes Age, social class, physical activity,
smoking, alcohol, preexisting CHD/
stroke, use of statins
Quartiles: Q4 vs. Q1





51.8 24.4 2 ALT, GGT Yes Age, systolic BP, family history of T2DM,
smoking, alcohol, exercise, FPG, TG,
HDL, HOMA, high-sensitivity CRP
Quartiles Q4 vs. Q1
ALT RR 2.20 (1.28e3.73) in men






44.0 25.6 20 ALT, AST Yes Age, gender, smoking, menopause,
alcohol
Per þ1 SD in logALT





49.5 26.0 7.0 GGT, ALT Yes Age, gender, education, smoking,
alcohol, physical activity, WC, systolic
BP, cholesterol, HDL, CRP, FPG
Quintiles Q5 vs. Q1






54.3 25.9 3.3 GGT, ALT, AST e Age, gender, alcohol, smoking Per þ10 U/l
GGT HR 1.09 (1.04e1.15)















































46.0 25.8 2 GGT Yes Age, family history of T2DM, smoking,
alcohol, ALT, OGTT, FPG, HbA1c, TG,
HOMA






61.4 24.3 4.2 GGT, ALT Yes Age, WC, cholesterol, HDL, TG, alcohol,
smoking, physical activity, follow-up
time, CRP
Quartiles Q4 vs. Q1
GGT OR 2.13 (1.33e3.41) in men
OR 2.69 (1.86e3.89) in women
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; CHD, coronary heart disease; FG, fasting plasma or serum glucose; FSI, fasting serum insulin; GGT,
gamma-glutamyltransferase; HDL, high-density lipoprotein cholesterol; HOMA, homeostasis model assessment for insulin resistance; HR, hazard ratio; IFG, impaired fasting glucose;
NAFLD, non-alcoholic fatty liver disease; OGTT, 2-hour oral glucose tolerance test; OR, odds ratio; RR, risk ratio; T2DM, type 2 diabetes; TG, triglyceride; US, ultrasonography; WC, waist
circumference.



















Fig. 1. Risk of T2DM in the mild and moderate/severe NAFLD compared to the non-NAFLD group. NAFLD was diagnosed by ultra-
sonography. Severity of NAFLD was defined based on NAFLD fibrosis score using the cut-off point <1.455 for mild and 1.455 for
moderate/severe NAFLD [68]. Analyzes are adjusted for age, sex, BMI, smoking, alcohol intake, exercise, family history of T2DM, total
cholesterol, triglycerides, HDL-cholesterol, HOMA-IR, high-sensitive CRP. Data are obtained from the study written by Chang et al.
[22] and shown as the hazard ratios and 95% confidence intervals. P-value for a trend was <0.001. HR, hazard ratio; NAFLD, non-
alcoholic fatty liver disease; T2DM, type 2 diabetes.
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In 12 of the 14 studies, either GGTor ALT or ASTor a combination of these enzymes was a significant
predictor of T2DM independently of age, BMI and alcohol consumption (Table 2). GGT was a significant
predictor in 10 of 11, ALT in 10 of 13 and AST in three of seven studies (Table 2). GGT and ALT predicted
T2DM even in the normal range (Fig. 2).Discussion
The data from the multiple available large studies document that NAFLD, diagnosed either by ul-
trasonography or elevated liver enzymes, predicts an increased risk of T2DM independently of age and
obesity. These results raise the question as to whether the presence of NAFLD should be used in clinical
practice to identify patients at risk for T2DM.
Ultrasonography-diagnosed NAFLD predicted T2DM in all studies, and in most studies after
adjustment for potential confounders. These studies were, however, performed in Asian subjects, with
the exception of one small study in Israelis (Table 1). Asian subjects, both those with NAFLD [39] and
those with T2DM [40,41] are leaner than Europid or American subjects. It is therefore uncertain
whether these data apply to non-Asian subjects. Since ultrasonography is unreliable and difficult to use
in obese subjects [42], it is possible that it is more sensitive to detecting T2DM risk in Asian subjects.
Ultrasonography is also inaccurate at quantifying liver fat percentages below 20e30% [43] which may
influence estimation of disease risk. On the other hand, ultrasonography is widely available and can
detect focal lesions in addition to providing a semi-quantitative estimate of steatosis.
Of the liver enzymes, it is well established that GGT is more sensitive to alcohol intake than ALT
[44,45]. Nevertheless, both GGT and ALT predicted T2DM even in studies which excluded excessive
alcohol use already at baseline [29e31], as well as in those statistically adjusting for alcohol intake
[25e30,32e38]. The relationship between ALT and risk of T2DM was linear and observed within the
normal range of ALT (Fig. 2B). Although ALT and GGT predicted T2DM on average, the correlation
between liver fat quantified by 1H-MRS, the state-of the art technique, and ALT is sex-dependent and
weaker than between liver fat and fasting serum insulin [46]. From the relationship between liver fat
and ALT, we could calculate that ALT is normal in 48% of subjects with NAFLD diagnosed by 1H-MRS
(liver fat content equal or greater than 5.56%), and 23% of subjects without NAFLD have increased ALT
(ALT >30 U/L inwomen,>40 U/L in men) [46]. This implies that ALT has major limitations as a predictor
of T2DM for individuals. AST is not very helpful either as it is less liver specific than ALT [47]. Consistent
with the present data (Fig. 2B and C), meta-analysis of prospective longitudinal studies found ALT but
not AST to increase the risk of T2DM [48].
Fig. 2. Risk of T2DM according to quintiles of liver enzymes GGT (panel A), ALT (panel B) and AST (panel C). Analyzes are adjusted for
age, BMI, smoking, alcohol intake, physical activity, family history of T2DM, fasting plasma glucose, white blood cell count, the other
liver enzymes including also alkaline phosphatase. Data are obtained from the study written by Nakanishi et al. [27] and shown as
the hazard ratios and 95% confidence intervals. P-value is presented for a trend. ALT, alanine aminotransferase; AST, aspartate
aminotransferase; GGT, gamma-glutamyltransferase; HR, hazard ratio; NS, non-significant; Q, quintile; T2DM, type 2 diabetes.
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also be caused by genetic variations in PNPLA3 [10] and TM6SF2 [12]. Neither ‘PNPLA3 NAFLD’
[10,49e57] nor ‘TM6SF2 NAFLD’ [12,58e60] are associated with insulin resistance. We did not identify
any studies, which examined whether NAFLD caused by these gene variants influenced the future risk
of T2DM. These variants do predict NASH, cirrhosis and HCC worldwide [14,61], but have not turned
out to be significant predictors of T2DM in the multiple genome-wide association studies searching for
genetic risk markers for T2DM [62].
In conclusion, abundant longitudinal studies especially in Asian populations using ultrasonography
have shown NAFLD to predict T2DM independently of confounders such as age and obesity. Liver
enzymes, especially ALT and GGT are also independent predictors of T2DM. While these studies
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they are not particularly useful in the clinic because of limitations in both ultrasonography and liver
enzymes as diagnostic tools, and because of the heterogeneity of NAFLD. Indeed, established methods
suchmeasurement of features of themetabolic syndrome and assessment of family history [63] remain
the gold standard for predicting risk of T2DM. On the other hand, physicians treating T2DM should not
forget to think of the liver and should measure at least liver enzymes in all patients as patients with
T2DMhave amarkedly increased risk of developing NASH [64] and cirrhosis [65] and even HCC [66,67].Research agenda
 Cost-effectiveness of imaging the liver in patients with the metabolic syndrome or type 2
diabetes
 Cost-effectiveness of genotyping for PNPLA3 and TM6SF2 variants in the identification of
subjects at risk for advanced liver disease in the clinic
Practice points
 Non-alcoholic fatty liver disease (NAFLD) is defined as hepatic steatosis not caused by excess
use of alcohol (>20 g/day in women, >30 g/day in men), viruses such as hepatitis B or C,
autoimmune hepatitis, use of hepatotoxic drugs, or rare genetic forms.
 NAFLD is currently the most common liver disorder with a prevalence of 25%
 NAFLD closely linked to the metabolic/insulin resistance syndrome is often observed in
obese subjects, but also independently obesity.
 Insulin resistance is not a characteristic of NAFLD due to the common genetic variations in
PNPLA3 or TM6SF2.
 ‘Metabolic/Obese NAFLD’ predicts T2DM independently of age and obesity and support the
role of hepatic insulin resistance in the pathogenesis of T2DM.Conflict of interest
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